• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.患者对肺癌维持化疗的理解和态度。
Patient Educ Couns. 2012 Oct;89(1):102-8. doi: 10.1016/j.pec.2012.04.013. Epub 2012 May 24.
2
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.维持厄洛替尼治疗晚期非小细胞肺癌亚洲患者的疗效和安全性:III 期随机 SATURN 研究的亚组分析。
Lung Cancer. 2012 Aug;77(2):339-45. doi: 10.1016/j.lungcan.2012.03.012. Epub 2012 Apr 10.
3
Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.晚期非小细胞肺癌的维持化疗:基于人群的 eligibility 评估。(注:这里“eligibility”结合语境推测可能是“适宜性”之类的意思,但按要求不做额外解释)
Lung Cancer. 2015 Mar;87(3):296-302. doi: 10.1016/j.lungcan.2014.12.014. Epub 2015 Jan 5.
4
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.长期缓解者肺功能改善的获益及副作用情况:对14例接受吉非替尼治疗至少9个月的非小细胞肺癌患者的分析
Lung Cancer. 2005 Oct;50(1):107-14. doi: 10.1016/j.lungcan.2005.05.006.
5
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.厄洛替尼对比化疗二线治疗晚期预后不良非小细胞肺癌患者的疗效和安全性(TITAN):一项随机、多中心、开放性、III 期研究。
Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.
6
Gefitinib for advanced non-small cell lung cancer.吉非替尼用于治疗晚期非小细胞肺癌。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2.
7
Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.吉非替尼联合立体定向放射治疗用于先前接受过治疗的晚期非小细胞肺癌患者。
Am J Clin Oncol. 2014 Apr;37(2):148-53. doi: 10.1097/COC.0b013e31826e071b.
8
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).随机 III 期临床试验:吉非替尼对比继续含铂双药化疗用于日本晚期非小细胞肺癌患者:来自 west Japan thoracic oncology group trial (WJTOG0203) 的结果。
J Clin Oncol. 2010 Feb 10;28(5):753-60. doi: 10.1200/JCO.2009.23.3445. Epub 2009 Dec 28.
9
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.吉非替尼单药治疗75岁及以上初治晚期非小细胞肺癌患者的II期试验。
J Thorac Oncol. 2008 Oct;3(10):1166-71. doi: 10.1097/JTO.0b013e318186a88d.
10
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.吉非替尼或厄洛替尼作为晚期非小细胞肺癌患者的维持治疗:系统评价。
PLoS One. 2013;8(3):e59314. doi: 10.1371/journal.pone.0059314. Epub 2013 Mar 21.

引用本文的文献

1
Symptoms of total pain experienced by older people with advanced gastrointestinal cancer receiving palliative chemotherapy.晚期胃肠道癌接受姑息化疗的老年人的全面疼痛症状。
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13674. doi: 10.1111/ecc.13674. Epub 2022 Aug 16.
2
Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China.肿瘤学家、患者及家属对肺癌治疗偏好的差异:一项中国的半结构化定性研究
Patient Prefer Adherence. 2021 Apr 15;15:775-783. doi: 10.2147/PPA.S299399. eCollection 2021.
3
Kidney cancer survivorship care: Patient experiences in a Canadian setting.肾癌生存护理:加拿大患者的经历。
Can Urol Assoc J. 2020 Nov;14(11):E560-E567. doi: 10.5489/cuaj.6217.
4
Quality of life versus length of life considerations in cancer patients: A systematic literature review.癌症患者生命质量与生存时间考量的系统文献回顾。
Psychooncology. 2019 Jul;28(7):1367-1380. doi: 10.1002/pon.5054. Epub 2019 May 15.
5
Patients and informal caregivers' experiences of burden of treatment in lung cancer and chronic obstructive pulmonary disease (COPD): a systematic review and synthesis of qualitative research.患者和非专业照护者在肺癌和慢性阻塞性肺疾病(COPD)治疗负担方面的体验:系统评价和定性研究的综合分析。
BMJ Open. 2019 Feb 5;9(2):e020515. doi: 10.1136/bmjopen-2017-020515.
6
Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.晚期非小细胞肺癌(NSCLC)患者一线及维持治疗期间的临床决策与健康相关生活质量:来自真实世界的研究结果
BMC Cancer. 2017 Aug 23;17(1):565. doi: 10.1186/s12885-017-3543-7.
7
Methodological Aspects of Focus Groups in Health Research: Results of Qualitative Interviews With Focus Group Moderators.健康研究中焦点小组的方法学问题:对焦点小组主持人进行定性访谈的结果
Glob Qual Nurs Res. 2016 Mar 14;3:2333393616630466. doi: 10.1177/2333393616630466. eCollection 2016 Jan-Dec.
8
Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis.肿瘤护理人员对患者使用电子门户的看法:一项定性分析。
Oncol Nurs Forum. 2017 Mar 1;44(2):165-170. doi: 10.1188/17.ONF.165-170.
9
Elucidating patient-perceived role in "decision-making" among African Americans receiving lung cancer care through a county safety-net system.通过一个县安全网系统,阐明非裔美国人在接受肺癌护理过程中患者所感知的“决策制定”角色。
J Cancer Surviv. 2016 Feb;10(1):153-63. doi: 10.1007/s11764-015-0461-z. Epub 2015 Jun 16.
10
Stigma among patients with lung cancer: a patient-reported measurement model.肺癌患者的耻辱感:一种患者报告的测量模型。
Psychooncology. 2014 Jan;23(1):81-92. doi: 10.1002/pon.3371. Epub 2013 Oct 3.

本文引用的文献

1
Patients rate physician communication about lung cancer.患者评价医生关于肺癌的沟通情况。
Cancer. 2011 Nov 15;117(22):5212-20. doi: 10.1002/cncr.26152. Epub 2011 Apr 14.
2
Rituximab maintenance therapy for follicular lymphoma.利妥昔单抗用于滤泡性淋巴瘤的维持治疗。
Lancet. 2011 Apr 2;377(9772):1151; author reply 1151-2. doi: 10.1016/S0140-6736(11)60459-5.
3
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.利妥昔单抗维持治疗对利妥昔单抗联合化疗后高肿瘤负荷滤泡性淋巴瘤患者的影响(PRIMA):一项 3 期随机对照试验。
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
4
Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.美国晚期非小细胞肺癌二线化疗的预测因素和影响:维持治疗的真实世界考虑因素。
J Thorac Oncol. 2011 Feb;6(2):365-71. doi: 10.1097/JTO.0b013e3181fff142.
5
Maintenance therapy in advanced non-small cell lung cancer: current status and future implications.晚期非小细胞肺癌的维持治疗:现状与未来意义。
J Thorac Oncol. 2011 Jan;6(1):174-82. doi: 10.1097/JTO.0b013e318200f9c5.
6
Race and lung cancer surgery--a qualitative analysis of relevant beliefs and management preferences.种族与肺癌手术——对相关观念及治疗偏好的定性分析
Oncol Nurs Forum. 2010 Nov;37(6):740-8. doi: 10.1188/10.ONF.740-748.
7
Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.超越监测、流行病学和终末结果:当代多样化人群中晚期非小细胞肺癌化疗管理模式。
J Thorac Oncol. 2010 Oct;5(10):1529-35. doi: 10.1097/JTO.0b013e3181e9a00f.
8
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.培美曲塞一线维持治疗晚期非鳞状非小细胞肺癌的成本效益分析。
J Thorac Oncol. 2010 Aug;5(8):1263-72. doi: 10.1097/JTO.0b013e3181e15d16.
9
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.厄洛替尼作为晚期非小细胞肺癌的维持治疗:一项多中心、随机、安慰剂对照的 3 期研究。
Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.
10
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.遏制海洋:维持化疗在转移性乳腺癌中的作用
Breast Cancer Res Treat. 2010 Jul;122(1):177-9. doi: 10.1007/s10549-010-0925-9. Epub 2010 May 11.

患者对肺癌维持化疗的理解和态度。

Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.

机构信息

Department of Internal Medicine, Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas 75390-9066, USA.

出版信息

Patient Educ Couns. 2012 Oct;89(1):102-8. doi: 10.1016/j.pec.2012.04.013. Epub 2012 May 24.

DOI:10.1016/j.pec.2012.04.013
PMID:22632736
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3443304/
Abstract

OBJECTIVE

Maintenance chemotherapy is a recently approved approach to the treatment of advanced non-small cell lung cancer (NSCLC). We sought to gain insight into patients' perceptions of maintenance chemotherapy using qualitative methods.

METHODS

We conducted thematic content analysis of focus groups at a freestanding cancer center and at an associated safety-net county hospital. Patients with advanced NSCLC who had started but not yet completed first-line platinum doublet chemotherapy were provided visual and written explanations of maintenance chemotherapy before being guided in group discussion.

RESULTS

Key themes to emerge for consideration of maintenance chemotherapy included: (1) survival benefits, disease control, and "buying time"; (2) the importance of "doing something"; (3) quality of life concerns; (4) the role of provider opinion/preference; and (5) the importance of logistics.

CONCLUSIONS

Patients undergoing first-line chemotherapy for advanced NSCLC were able to understand the concept of maintenance chemotherapy, distinguish it from traditional treatment paradigms, identify pros and cons of this approach, and convey reasons for considering it.

PRACTICE IMPLICATIONS

Advances in oncology care that alter therapy modalities and delivery may significantly impact patient perceptions and treatment experiences. Clinical team members may wish to elicit treatment preferences of first-line patients through clinical discussion that anticipate these considerations.

摘要

目的

维持化疗是最近批准的治疗晚期非小细胞肺癌(NSCLC)的方法。我们试图通过定性方法深入了解患者对维持化疗的看法。

方法

我们在一家独立的癌症中心和一家附属的安全网县医院进行了焦点小组的主题内容分析。在开始但尚未完成一线铂类双联化疗的晚期 NSCLC 患者在接受维持化疗的群体讨论之前,他们接受了维持化疗的视觉和书面解释。

结果

考虑维持化疗的关键主题包括:(1)生存获益、疾病控制和“争取时间”;(2)“做些什么”的重要性;(3)生活质量问题;(4)提供者意见/偏好的作用;以及(5)后勤的重要性。

结论

接受一线化疗治疗晚期 NSCLC 的患者能够理解维持化疗的概念,将其与传统治疗模式区分开来,识别这种方法的优缺点,并说明考虑这种方法的原因。

实践意义

改变治疗方式和方法的肿瘤学进展可能会极大地影响患者的看法和治疗体验。临床团队成员可能希望通过预期这些考虑因素的临床讨论来征求一线患者的治疗偏好。